Background
Liver cancer represents one of the most frequent malignant diseases in China and the global [
1,
2]. According to a histopathological perspective, more than 90% of liver cancer belongs to hepatocellular carcinoma (HCC). Over 450,000 HCC cases were newly diagnosed, and 420,000 HCC patients were dead in 2015 in China [
1]. The mortality rate of HCC ranks the second most common cause of cancer-related death in men and the sixth in women. Unfortunately, the molecular mechanisms of HCC development and progression remain so far obscure. Previous literatures indicate that deregulation of genes involved in cell cycle regulation contributes to the hepatocarcinogenesis [
3,
4]. Studies focus on the role of such genes may provide clinical significance to the management of HCC.
Sperm-associated antigen 5 (SPAG5, also known as Astrin and hMAP126), mapped to Ch17q11.2, was originally identified as a microtubule-associated protein that was associated with spindles throughout mitosis and localized to kinetochores of congressed chromosomes [
5,
6]. SPAG5 contains a N-terminal globular domain and two predicted coiled-coil domains. SPAG5 has been demonstrated to interact with many proteins, such as Aurora-A [
7], PLK1 [
8] and GSK3β [
9] to modulate the spindle apparatus organization and chromosome segregation, making SPAG5 essential in the cell growth. Centrosome instability and malformation of the spindle were observed in SPAG5-depleted cells [
10]. Silencing of SPAG5 suppressed the growth of HeLa cells and resulted in the formation of multipolar and highly disordered spindles [
11]. Overexpression of SPAG5 was reported in cervical cancer, pancreatic cancer and non-small-cell lung cancer [
12‐
14]. Amplification or gain of the SPAG5 locus occurring in 10–19% of breast cancers was correlated with poor clinical outcome and adverse clinicopathological features [
15]. Furthermore, the upregulation of SPAG5 affected the response of cancer cells to chemotherapy [
12,
15]. These data strongly link SPAG5 to the progression of human cancers. However, the clinical significance of SPAG5 and its role in HCC are still unclear.
Using tissue microarray, and in vitro and in vivo models, we intended to examine the expression and clinical value of SPAG5 in HCC, and to explore the role of SPAG5 in HCC cell growth and the underlying mechanisms. Our data suggest SPAG5 serve as a potential prognostic factor and function as an oncogene via CEP55-mediated PI3K/AKT pathway in HCC.
Methods
Patients
Twenty-seven fresh HCC specimens were collected for determination of mRNA and protein levels of SPAG5 from Sun Yat-sen University Cancer Center (SYSUCC). A cohort of 298 paraffin-embedded HCC cases diagnosed between Jan 2012 to Dec 2013 at Dongguan Third People’s Hospital and SYSUCC was recruited. Another 93 HCC samples with venous metastases were obtained from SYSUCC. None of the patients had received radiotherapy or chemotherapy before surgery. All samples were anonymous. This project was approved by Institute Research Ethics Committee of the above two hospitals. The clinical implication of SPAG5 was further determined in The Cancer Genome Atlas (TCGA) dataset (
http://www.cbioportal.org) and the Oncomine dataset (
https://www.oncomine.org).
Cell culture and transfection
HCC cell lines PLC8024, Huh7 and QGY-7703 were purchased from the Cell Resource Center, Chinese Academy of Science Committee (Shanghai, China). Cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco, Gaithersburg, MD, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS, Hyclone, Logan, UT) in a humidified incubator at 37 °C and 5% CO2. The cells were transfected with SPAG5 overexpression vector or shRNAs by Lipofectamine 2000, according to the instruction, and then selected by G418 for 4 weeks to establish stable cells.
Quantitative real-time polymerase chain reaction (qRT-PCR)
qRT-PCR was performed according to our previous study. The sequences of the PCR primers are as followings: SPAG5, forward: 5′- CATCTCACAGTGGGATAACTAATAAAC-3′ and reverse: 5′- CAGGGATAGGTGAAGCAAGGATA-3′; CEP55, forward: 5’-TGAAGAGAAAGACGTATTGAAACAA-3′ and reverse: 5′- ACTGTGGCTCCAAACTGCTT-3′; β-actin, forward: 5’-TGGCACCCAGCACAATGAA-3′ and reverse: 5’-CTAAGTCATAGTCCGCCTAGAAGCA-3′. The relative expression of SPAG5 and CEP55 was presented as –ΔCT value.
Western blot
Equal amounts of protein (30 μg) were resolved by SDS-PAGE and then electrophoretically transferred onto PVDF membranes (Millipore, Bedford, MA). After blocked in 5% non-fat milk 1 h at room temperature, the membranes were incubated with appropriately diluted primary antibodies overnight at 4 °C. After washed twice with TBST, the blotted membranes were incubated with HRP-conjugated secondary antibody at 1:20000 dilutions for 1 h at room temperature. The membranes were visualized by the enhanced Phototope TM-HRP Detection Kit and exposed to Kodak medical X-ray processor (Carestream Health, USA). The primary antibodies are as followings: SPAG5, 1:500 (Sigma-Aldrich), CEP55 (1:1000, #81693, Cell Signaling Technology), AKT (1:1000, #2920, Cell Signaling Technology), p-AKT at Ser473 (1:1000, #4046, Cell Signaling Technology), ERK1/2 (1:1000, #4695, Cell Signaling Technology), p-ERK1/2 at Thr202/Tyr204 (1:1000, #4370, Cell Signaling Technology), E-Cadherin, β-Catenin, N-Cadherin, Vimentin, Fibronectin and MMP-2 (Epitomics, Burlingame, CA) and β-actin (1:1000, #3700, Cell Signaling Technology).
Immunohistochemistry (IHC)
IHC staining was performed on a HCC tissue microarray (TMA). The expression levels were scored as proportion of immunopositive staining area (0%, 0; 1–25%, 1; 26–50%, 2; 51–75%, 3; 76–100%, 4) multiplied by intensity of staining (0, negative; 1, weak; 2, moderate; 3, intense). The scores were independently rendered by two pathologists (Dr. Yang YF and Dr. Zhang MF). The median IHC score (4.0) was chosen as the cut-off value to define high and low expression.
Stable cells were constructed. Cells were collected and seeded in 6-well plates at a density of 1.0 × 103 per well, and then incubated for 14 days. Colonies were fixed with methanol, stained with 0.1% crystal violet and counted.
Transwell assay
A total of 3.0 × 104 cells were re-suspended in 200 μl of serum-free medium and placed in the upper compartment of a Transwell chamber (Corning; 24-well insert, pore size: 8 mm). The lower chamber was filled with 15% fetal bovine serum as a chemo attractant and incubated for 48 h for the migration assay. After 48 h, the cells on the upper surface of the membrane were removed, and the cells on the lower surface were fixed and stained with 0.1% crystal violet. Five visual fields of each insert were randomly chosen and counted under a light microscope.
Luciferase reporter assay
PLC8024 cells were co-transfected with miR-363-3p mimics or the negative control and psiCHECK-2-SPAG5–3’-UTR reporter. Cells were collected 36 h after transfection and analyzed with the Dual-Luciferase Reporter Assay System (Promega, CA, USA).
Animal model
Male BALB/c nude mice aged 3–4 weeks were randomly divided into two groups. Four million cells were implanted subcutaneously under the right armpits into the flanks of the mice. Each group included 6 mice. Tumor size and body weight were measured once every 3 days. Four weeks later, the mice were sacrificed, and tumor weight and size were measured again. Volumes were calculated using the following formula: Volume (mm3) = [width2 (mm2) × length (mm)]/2. For metastasis observations, five-week-old male nude BALB/c mice were injected with 5 × 105 cells via the tail vein. Six weeks later, the mice were killed. The lungs of the mice were fixed and stained with hematoxylin and eosin. Lung metastasis was quantified by counting the number of tumor nodule in 10 randomly selected high-power fields. All animal studies were conducted with the approval of the Medical Experimental Animal Care Commission of SYSUCC.
Statistical analysis
The Student’s t-test was used for comparisons between groups. Kaplan–Meier analyses were used for survival analysis. Differences were considered significant for P-values less than 0.05. All data from three separate experiments are presented as mean ± SEM.
Discussion
HCC represents the fifth most common malignant tumor worldwide and has been becoming a global threat to human life [
1]. Although HCC has been extensively studied, the detailed molecular events in the disease’s development are still elusive. More potential markers useful for the prediction of HCC progression and prognosis are required to provide clinical significances. In this study, we showed that high SPAG5 expression was associated with aggressiveness and poor prognosis of HCC patients independent of other clinical features. Overexpression of SPAG5 significantly enhanced the proliferative and migrated ability of HCC cells via the interaction with CEP55 to trigger the PI3K/AKT signaling pathway (Fig.
6e). Our data suggest SPAG5 functions as an oncogene to promote HCC and therefore serves as a promising therapeutic target for the intervention of HCC.
Identification of proteins with prognostic value may contribute to tumor classification and the development of novel therapies against human cancers. The clinical impact of SPAG5 has been well documented in breast cancer. Copy number aberration of SPAG5, as well as the high expression of SPAG5 transcript and protein, contributed to the worse overall and cancer-specific survival of patients with breast cancer [
15]. Upregulation of SPAG5 in cervical cancer was reported to associate with poor prognosis [
12]. In two independent cohorts containing 670 HCC patients, we found that patients with increased expression of SPAG5 were frequently accompanied with shorter survival. This might be attributed to the fact that high expression of SPAG5 was correlated with unfavorable clinical parameters, including poor tumor differentiation, larger tumor size, advanced TNM stage, tumor vascular invasion and lymph node metastasis. Furthermore, our in vitro and in vivo data demonstrated that cancer cells with SPAG5 overexpression were more aggressive. These data suggest SPAG5 is involved in the progression of human cancers.
Post-transcriptional modulation of mRNA is responsible for the dysregulation of microtubule proteins. SPAG5 was previously demonstrated to be targeted by miR-539 in prostate cancer [
16]. In this study, we identified miR-363-3p as an upstream regulator to suppress the expression of SPAG5 in HCC cells. Overexpression of miR-363-3p markedly inhibited the cell growth and migration, which could be markedly attenuated by SPAG5 overexpression. Further data indicated that miR-363-3p reduced SPAG5 expression via suppression of the promoter activity of SPAG5 mRNA. The role of miR-363-3p in HCC was reported by Zhou and colleagues. Their data showed that miR-363-3p blocked the cell proliferation via S1PR1-mediated silence of ERK and STAT3 signaling pathways [
17].
The investigation of the biological function of SPAG5 in HCC demonstrated that SPAG5 exerted oncogenic activities to promote tumor growth and metastasis via interaction with CEP55. CEP55 (FLJ10540, C10orf3) was mapped to the 10q23 chromosomal region, with a cellular localization to centrosome throughout mitosis [
18]. Overexpression of CEP55 has been reported in colon cancer [
19], head and neck cancer [
20], lung cancer [
21], oral cavity squamous cell carcinoma [
22] and HCC [
23]. High expression of CEP55 activated prosurvival signaling pathways, resulting in cancer cell proliferation and migration. Chen et al. showed that CEP55 facilitated cellular transformation through the activation of PI3K/AKT pathway via protein interaction [
24]. In the present study, SPAG5 physically bound to CEP55. The inhibition of PI3K/AKT signaling remarkably abolished the SPAG5-promoted cell growth. Collectively, these data suggest SPAG5/CEP55/AKT axis might be a potential therapeutic target in HCC.
Conclusions
In summary, we show that increased expression of SPAG5 in HCC was closely correlated with poor outcomes, indicating that SPAG5 serves a promising prognostic factor in HCC. Our data demonstrate SPAG5 functions as an oncogene via CEP55-mediated PI3K/AKT pathway. The newly identified miR-363-3p/SPAG5/CEP55 axis may represent a potential therapeutic target for the clinical intervention of HCC.